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Pheochromocytoma and paraganglioma (PPGLs) are rare catecholamine-secreting neuroendocrine tumors but can be life-threaten-
ing. Although most PPGLs are benign, approximately 10% have metastatic potential. Approximately 40% cases are reported as har-
boring germline mutations. Therefore, timely and accurate diagnosis of PPGLs is crucial. For more than 130 years, clinical, molecu-
lar, biochemical, radiological, and pathological investigations have been rapidly advanced in the field of PPGLs. However, perform-
ing diagnostic studies to localize lesions and detect metastatic potential can be still challenging and complicated. Furthermore, great 
progress on genetics has shifted the paradigm of genetic testing of PPGLs. The Korean PPGL task force team consisting of the Kore-
an Endocrine Society, the Korean Surgical Society, the Korean Society of Nuclear Medicine, the Korean Society of Pathologists, and 
the Korean Society of Laboratory Medicine has developed this position statement focusing on the comprehensive and updated diag-
nosis for PPGLs.
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SUMMARY
1. New classification of pheochromocytoma/paraganglioma
1.1. All pheochromocytoma and paraganglioma (PPGLs) are considered to have metastatic potential. The terms “benign” and 
“malignant” should not be used to distinguish non-metastatic PPGLs from metastatic PPGLs (A).
1.2. The tumor-node-metastasis (TNM) staging system should be evaluated in diagnosing PPGLs (A). 
2. Biochemical tests of pheochromocytoma/paraganglioma
2.1. Initial biochemical tests of PPGL should include measurements of plasma free metanephrines or urinary fractionated 
metanephrines (A).
2.2. Measurements of urinary dopamine and plasma 3-methoxytyramine are useful for the biochemical diagnosis of PPGLs 
with predominantly dopamine secretion and/or high risk for metastases (C).
2.3. Chromogranin A can be used as a biomarker for biochemically silent PPGL (PPGL with normal metanephrine, normeta-
nephrine, and 3-methoxytyramine) (C).
3. Imaging of pheochromocytoma/paraganglioma
3.1. Once here is clear biochemical evidence of a PPGL, anatomic imaging by computed tomography (CT) is the first-choice 
imaging modality to locate PPGLs. Magnetic resonance imaging is the second-choice imaging method when CT findings 
are inconclusive or when patients are poor candidates to undergo contrast-enhanced CT (A). 
3.2. Functional imaging is recommended for evaluating disease characteristics and detecting metastases, particularly in pa-
tients with a high-risk for metastases and multifocal diseases (e.g., lager tumor size >5.0 cm, extra-adrenal, bilateral, or 
hereditary) (A).
3.3. We suggest 123I-metaiodobenzylguanidine (MIBG) scintigraphy/single-photon emission computed tomography (SPECT), 
gallium 68 (68Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-somatostatin receptor analogs (SSA) 
positron emission tomography (PET)/CT, or fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) PET/CT as the functional 
imaging modality according to the genotype, location, availability of radiopharmaceuticals, and clinical situation (B). 
3.4. In PPGL patients planning for 131I-MIBG treatment, 123I-MIBG is necessary for treatment decision and response monitor-
ing. 68Ga-DOTA-SSA PET/CT is necessary in patients with metastatic PPGLs when peptide receptor radionuclide therapy 
(PRRT) is planned (B). 
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INTRODUCTION
Pheochromocytomas and paragangliomas (PPGLs) are rare 
chromaffin cells-derived tumors that originated from the adre-
nal medulla and the extra-adrenal sympathetic or parasympa-
thetic paraganglia, respectively. The overall annual incidence of 
PPGLs is estimated to be two to eight cases per million, and the 
recent report in Korea showed the annual incidence of 1.8 cases 
per million [1-4].
PPGLs release catecholamines, mainly norepinephrine and 
epinephrine, causing hypertension, headache, sweating, and 
palpitations. If not recognized, PPGLs can severely affect the 
cardiovascular, gastrointestinal, and other systems, and can 
threaten patients by causing such as fatal arrhythmia, myocardi-
al infarction, cerebrovascular events, and sudden death [5-7]. 
PPGLs have the potential for metastases, in the case of meta-
static PPGLs, found in the presence of tumors derived from 
chromaffin cells in non-chromaffin organs at the time of diag-
nosis or during the follow-up period [8]. According to a recently 
published study, metastases were already detected in 9.0% of 
patients with PPGLs at the initial diagnosis, and 9.5% of metas-
tases occurred during the follow-up period [1]. Excess of cate-
cholamine, as well as metastases involve in increased morbidity 
and mortality in PPGLs patients [9-11]. Therefore, timely and 
accurate diagnosis and treatment of PPGLs is essential. 
In recent years, with the advancement of next-generation se-
quencing (NGS) technology, the genetic discoveries of PPGLs 
have increased significantly, and at least 30% of these tumors 
have been identified as hereditary [12]. Over the past decade, 
our knowledge in the field of PPGLs has been rapidly expanded 
and changed by many discoveries in genetics, biochemical, im-
aging diagnosis, and treatment of these tumors. Therefore, the 
modifications in the fourth edition of the World Health Organi-
zation (WHO) classification in 2017 is primarily based on the 
novel findings on the clinical behaviors and genetics of adrenal 
tumors [13]. There have been exponential advances in the ge-
netics of these tumors according to the progress in NGS tech-
nology, and in recent years, new susceptible genes with germ-
line and somatic mutations have been discovered [12,14,15]. In 
addition to catecholamines, various products secreted by PP-
GLs, such as chromogranin A, have begun to be applied as use-
ful biochemical diagnostic markers [16]. Beyond the traditional 
functional imaging study with 123I-metaiodobenzylguanidine 
(MIBG) scintigraphy, the emerged molecular imaging tech-
niques, such as 11C-hydroxyephedrine positron emission tomog-
raphy/computed tomography (PET/CT) and gallium 68 (68Ga) 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA)-somatostatin receptor analogs (SSA) PET/CT, have 
4. Pathological grading system of pheochromocytoma/paraganglioma
4.1. The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading of Adrenal Pheochromocytoma and 
Paraganglioma (GAPP) cannot be used to confirm the diagnosis of malignancy (B).
4.2. The loss of succinate dehydrogenase B (SDHB) protein by immunohistochemistry staining in tumor cells is suggested to 
detect the presence of germline mutations in one of the SDHx genes. PPGLs associated with SDHB mutation have a high 
risk of metastases (B).
5. Genetic testing for pheochromocytoma/paraganglioma
5.1. Genetic testing is recommended in all patients diagnosed with PPGLs (A).
5.2. Genetic testing should be also considered for first-degree relatives of patients with hereditary PPGLs (B). 
5.3. Validated targeted next-generation sequencing (NGS) is a preferred method for the genetic diagnosis of PPGLs (B). 
5.4. We recommend targeted NGS panels of gene sets based on the current level of evidence of their pathogenic driver status: 
10 basic panel (fumarate hydratase [FH], myc-associated protein X [MAX], neurofibromatosis 1 [NF1], rearranged during 
transfection [RET], succinate dehydrogenase A [SDHA], SDHB, SDHC, SDHD, transmembrane protein 127 [TMEM127], 
von Hippel-Lindau [VHL]) and five extended panel (egl-9 family hypoxia inducible factor 1/prolyl hydroxylase domain 2 
[EGLN1/PHD2], endothelial PAS domain-containing protein 1 [EPAS1], kinesin family member 1B [KIF1B], receptor ty-
rosine kinase [MET], succinate dehydrogenase complex assembly factor 2 [SDHAF2]) (C).
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been introduced for the precise diagnosis for localization and 
staging [17,18]. 
In accordance with the revised international recommenda-
tions and advanced diagnostic techniques, the PPGL task force 
team has developed the guideline for the diagnosis of PPGLs, 
regarding controversial issues in South Korea. The following 
will discuss the changes noted in the new WHO classification 
and provide updates on genetic, biochemical, and imaging diag-
nostic approaches of the PPGLs. 
METHODS 
Development of evidence-based recommendations 
This guideline was developed by the multidisciplinary commit-
tee, which comprises the Korean Endocrine Society, the Korean 
Surgical Society, the Korean Society of Nuclear Medicine, the 
Korean Society of Pathologists, the Korean Society of Radiolo-
gy, and the Korean Society of Laboratory Medicine. The guide-
line included the most current evidence-based recommendations 
for diagnosis of PPGLs. The grading system included the fol-
lowing considerations: numbers of well-designed randomized 
controlled trials, meta-analysis results, cohort studies, patient–
control studies, or expert opinion on clinical experiences. The 
guideline committee’s grading system uses A, B, C, or E to 
present the evidence level supporting each recommendation, as 
defined in the previous study (Table 1) [19].
DISCUSSION OF THE RECOMMENDATIONS 
1. New classification of pheochromocytoma/paraganglioma 
Substantial changes have been included regarding the topics of 
adrenal tumors in the fourth edition of the WHO classification 
of endocrine tumors published in 2017 compared to the third 
edition of 2004 [20,21]. In the 2017 version of the WHO classi-
fication, information on ‘tumors of the adrenal medulla and ex-
tra-adrenal paraganglia’ has been described in an independent 
chapter and has been separated from the chapter discussing the 
‘tumors of the adrenal cortex’ [20]. Table 2 summarizes the 
WHO classification of tumors of the adrenal medulla and extra-
adrenal paraganglia [20]. 
1.1.  All PPGLs are considered to have metastatic potential. 
The terms “benign” and “malignant” should not be 
used to distinguish non-metastatic PPGLs from 
metastatic PPGLs (A).
Prior to the update on adrenal tumors in 2017 WHO of endo-
crine tumors, PPGLs have traditionally been classified as “ma-
lignant” and “benign” based on the presence of distant metasta-
Table 1. Summary of Strength of Evidence for Recommendations
Definition of the recommendation level
A When there is a clear rationale for the recommendations:  
When multiple randomized controlled trials that can be generalized because they have sufficient test or meta-analysis results supports a 
recommendation. 
B When there is a reliable basis for the recommendation:  
When reasonable grounds support this through well-performed cohort studies or patient–control group studies. 
C When there is a possible basis for the recommendations:  
When relevant grounds are seen through randomized clinical studies or case reports and observational studies carried out in a small institu-
tion, despite their inherent unreliability.
E Expert recommendations:  
There is no basis to support the recommendations, but they are supported by expert opinion or expert clinical experience.
Adapted from Kim et al. [19].
Table 2. Updated Version of 2017 World Health Organization 
Classification of Tumors of the Adrenal Medulla and Extra-Ad-
renal Paraganglia
Pheochromocytoma
Head and neck paraganglioma
Sympathetic paraganglioma
Neuroblastic tumour of the adrenal gland
   Neuroblastoma
   Ganglioneuroblastoma, nodular
   Ganglioneuroblastoma, intermixed
   Ganglioneuroma
Composite pheochromocytoma
Composite paraganglioma
Ku EJ, et al.
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ses. Metastases occur in approximately 5% to 10% of pheochro-
mocytomas [8]. Several relevant indicators based on histopa-
thology, immunohistochemistry (IHC), genetic mutations and 
molecular biological characteristics such as the Pheochromocy-
toma of the Adrenal Gland Scaled Score (PASS) grading sys-
tem, the Grading of Adrenal Pheochromocytoma and Paragan-
glioma (GAPP), and the composite pheochromocytoma/para-
ganglioma prognostic score (COPPs) scoring system have been 
proposed to predict metastatic potential [22-26]. However, these 
scoring systems is not well-validated for the prediction of the 
metastatic tumors. Due to the lack of the approved histological 
system on PPGL’s biological aggressiveness, all PPGLs are 
considered to have metastatic potential. Therefore, the terms 
“malignant” and “benign” are abandoned and combined into a 
single section “pheochromocytoma” in the updated version of 
WHO classification of endocrine tumors [20]. In addition, in the 
current version of the WHO classification, “malignant” was re-
placed with the term “metastatic” to clearly distinguish between 
locally invasive and distant metastatic PPGLs.
1.2.  The TNM staging system should be evaluated in 
diagnosing PPGLs (A). 
The first staging system for PPGL was published by the Ameri-
can Joint Committee on Cancer (AJCC) in 2017. The AJCC 
TNM (T, size and location of primary tumor; N, regional lymph 
node metastases; and M, presence and location of distant metas-
tases) staging system helps to make treatment and prognostic 
related decisions and provides standardized communicative de-
scription tools for the tumor. The TNM classification system for 
PPGLs reflects the prognostic factors that predict the metastases 
and shorter survival, and these predictors include the large size 
of the primary tumor (≥5.0 cm), extra-adrenal tumor, and the 
presence of distant metastases (e.g., bone, liver, lungs, and 
lymph nodes) (Table 3) [27]. While smaller (<5.0 cm) tumors 
rarely occur distant metastases, patients with larger (≥5.0 cm) 
tumors have lower overall survival rates due to the increased 
risk of distant metastases [28,29]. Therefore, pheochromocyto-
mas are divided into T1 (<5.0 cm) and T2 (≥5.0 cm) according 
to the tumor size. Tumors with the invasion of surrounding tis-
sues such as liver or kidneys are classified as T3 because they 
need extensive surgery and usually tend to be more aggressive 
[30]. Also, the location of the primary tumors is an important 
predictive factor of metastases. Sympathetic paragangliomas 
(PGLs) are associated with higher metastatic potential and 
shorter overall survival rates regardless of the primary tumor 
size, so these are reflected in T staging [29]. Patients with meta-
static PPGLs have high morbidity and mortality rates due to the 
excessive catecholamines, and patients with metastatic PPGLs 
have a significantly lower 5-year survival rate compared to pa-
tients without metastases (90% vs. 60%) [31,32]. Similarly, a 
recent nationwide population-based epidemiological study in 
South Korea showed the hazard ratio for mortality of patients 
with metastatic PPGLs was twice higher compared to patients 
without metastatic PPGLs [1]. The common metastatic sites of 
metastatic PPGLs are the regional and distant lymph nodes, 
bone, liver, and lungs [33,34]. Among common metastatic sites, 
bone metastases are known be less aggressive with a longer me-
dian overall survival (12 years) compared with non-skeletal me-
tastases (5 to 7.5 years) [35]. Given that the median survival 
rates differ according to the metastatic sites, M staging of AJCC 
was determined by the location of the distant metastases [32].




   pTX: primary tumor cannot be assessed
   pT1: pheochromocytoma <5 cm in greatest dimension
   pT2: pheochromocytoma ≥5 cm or sympathetic paraganglioma 
   pT3:  invasion into surrounding tissues (including extra-adrenal adi-
pose) 
Regional lymph nodes (pN)b
   pNX: regional lymph nodes cannot be assessed 
   pN0: no regional lymph node metastasis 
   pN1: regional lymph node metastasis 
Distant metastases (pM)
   M0: no distant metastasis
   pM1a: metastasis to bone
   pM1b: metastasis to non-regional lymph node, liver or lung 
   pM1c: metastasis to bone and multiple other sites
AJCC prognostic stage groups 
   Stage I: T1 N0 M0 
   Stage II: T2 N0 M0 
   Stage III: T1-2 N1 M0 or T3 any N M0    
   Stage IV: any T any N M1 
AJCC, American Joint Committee on Cancer; TNM, tumor-node-me-
tastasis.
aNonfunctional parasympathetic paragangliomas (arising from the head 
and neck) are excluded in this staging; bRegional lymph nodes includes 
aortic and retroperitoneal nodes for abdominal and pelvic tumors.   
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2. Biochemical tests of pheochromocytoma/paraganglioma
2.1.  Initial biochemical tests of PPGL should include 
measurements of plasma free metanephrines or 
urinary fractionated metanephrines (A).
Evidence of catecholamine excess is an essential prerequisite 
for the clinical diagnosis of PPGL. Metanephrines are the O-
methylated metabolites of epinephrine and norepinephrine. 
They are produced within the cytoplasm of adrenal chromaffin 
cells or PPGL tumor cells by catechol-O-methyltransferase. 
This process occurs continuously and independently from exo-
cytic catecholamine release, which is the theoretical basis of su-
perior sensitivity of measuring metanephrines than catechol-
amines for the diagnosis of PPGL.
Previous clinical studies consistently reported superior sensi-
tivity and specificity of metanephrines than other biochemical 
tests for PPGL. One of the early studies, which included 214 
pheochromocytoma patients from National Institutes of Health 
(NIH) and European centers, demonstrated a sensitivity of 99% 
and specificity of 89% for plasma free metanephrines [36]. The 
diagnostic performance of plasma free metanephrines was sig-
nificantly higher than urinary catecholamines or vanillylmandel-
ic acid based on the receiver operating curve analysis. A meta-
analysis of the diagnostic accuracy of plasma free metanephrines 
estimated the pooled sensitivity and specificity as 97% and 94% 
[37].
Several studies compared the diagnostic accuracy of urinary 
fractionated metanephrines and plasma free metanephrines. 
Plasma free metanephrines showed a higher sensitivity and 
specificity than urinary fractionated metanephrines [36,38-41]. 
However, the difference was small and not statistically signifi-
cant. Currently, no priority was recommended between plasma 
free metanephrines and urinary fractionated metanephrines.
The diagnostic accuracy of metanephrines was also evaluated 
in Korean PPGL patients. In a single-center study of 28 patients 
and 156 control subjects, plasma free metanephrines showed 
sensitivity and specificity of 96% and 76%, respectively. Uri-
nary fractionated metanephrines showed sensitivity and speci-
ficity of 96% and 94%, respectively [42]. Another study en-
rolled patients from two large Korean centers also reported high 
diagnostic accuracy of urinary fractionated metanephrines [43].
For accurate measurement and interpretation of metaneph-
rines, measurement methods, sampling conditions and cut-offs 
of the assay should be considered. Liquid chromatography with 
mass spectrometric or electrochemical detection methods is 
highly accurate and reproducible with low risk of interference. 
The position of blood sampling should be considered when in-
terpreting the results of plasma free metanephrines. Previous 
studies used blood sampling in the supine position. Upright po-
sitioning stimulates norepinephrine release and subsequently in-
creases plasma normetanephrine. Seated sampling generally re-
ported higher cut-off for diagnosing PPGL and lower specificity 
than supine sampling [44]. Thus, supine position is recommend-
ed for blood sampling, especially when retesting after equivocal 
elevation of metanephrines.
2.2.  Measurements of urinary dopamine and plasma 
3-methoxytyramine are useful for the biochemical 
diagnosis of PPGLs with predominantly dopamine 
secretion and/or high risk for metastases (C).
As metanephrines are metabolites of epinephrine and norepi-
nephrine, 3-methoxytyramine is O-methylated metabolite of 
dopamine produced by catechol-O-methyltransferase. Plasma 
3-methoxytyramine level can be elevated in PPGL patients due 
to the excess production of dopamine. The diagnostic accuracy 
of plasma 3-methoxytyramine for the diagnosis of overall PPGL 
is not superior to metanephrines. The addition of plasma 3-me-
thoxytyramine to plasma free metanephrines did not signifi-
cantly increase the diagnostic accuracy for PPGL [45]. Howev-
er, for some PPGLs that produce dopamine predominantly, 
plasma 3-methoxytyramine can provide superior diagnostic 
utility than metanephrines. Plasma 3-methoxytyramine was ele-
vated in dopamine-producing PGLs by nearly 100-folds, sug-
gesting high discriminative power of plasma 3-methoxy-
tyramine for dopamine-producing PPGLs [46]. 
Elevated plasma 3-methoxytyramine is associated with a high 
risk of metastatic PPGL. In a large European cohort of 365 
PPGL patients, 105 patients with metastatic PPGL showed sig-
nificantly higher plasma 3-methoxytyramine and urinary dopa-
mine [47]. The mean plasma 3-methoxytyramine level was 
higher by nearly 4-folds in metastatic PPGL than non-metastatic 
PPGL. In addition, succinate dehydrogenase B (SDHB) mutant 
PPGL showed increased production of dopamine in the tumor 
metabolomics and had high plasma and urinary dopamine and 
plasma 3-methoxytyramine levels [48]. SDHB mutation confers 
a high risk of metastases, which, at least partly, explains the 
high risk of metastases in PPGL with elevated dopamine and 
3-methoxytyramine.
2.3.  Chromogranin A can be used as a biomarker for bio-
chemically silent PPGL (PPGL with normal metanep-
hrine, normetanephrine, and 3-methoxytyramine) (C).
Chromogranin A serves an important role in the formation of 
Ku EJ, et al.
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secretory granules of neuroendocrine cells. Plasma or serum 
chromogranin A level is elevated in patients with neuroendo-
crine tumors. Chromogranin A is highly sensitive and specific 
for PPGLs when differentiating PPGL patients from normal in-
dividuals [49,50]. Chromogranin A was still elevated in bio-
chemically silent PPGLs with normal metanephrine, normeta-
nephrine and methoxytyramine [51]. The histologic evaluation 
in silent PPGLs showed preserved secretory granule without the 
expression of tyrosine hydroxylase, which explains the molecu-
lar mechanism of elevated chromogranin A in biochemically si-
lent PPGLs.
3. Imaging of pheochromocytoma/paraganglioma
3.1.  Once there is clear biochemical evidence of a PPGL, 
anatomic imaging by CT is the first-choice imaging 
modality to locate PPGLs. MRI is the second-choice 
imaging method when CT findings are inconclusive or 
when patients are poor candidate to undergo contrast-
enhanced CT (A). 
For the localization of PPGLs, both CT and magnetic resonance 
imaging (MRI) are highly sensitive. CT with contrast provides 
an excellent detection rate between 88% and 100% [52-54]. 
Considering that most PPGLs are located in the abdomen, a CT 
scan of the abdomen and pelvis should be the first anatomical 
imaging modality. CT is preferred to MRI for the detection of 
lung metastases, while MRI shows better sensitivity between 
90% and 95% for detecting skull base and neck PGLs than CT 
[55,56]. MRI is also preferred in patients with an allergy to CT 
contrast agent, and in patients in whom radiation exposure 
should be limited (i.e., children, pregnant women, patients with 
known germline mutations, and those with recent excessive ra-
diation exposure) [57].
3.2.  Functional imaging is recommended for evaluating 
disease characteristics and detecting metastases, 
particularly in patients with a high-risk for metastases 
and multifocal diseases (e.g., lager tumor size >5.0 cm, 
extra-adrenal, bilateral, or hereditary) (A).
3.3.  We suggest 123I-MIBG scintigraphy/scintigraphy/ 
single-photon emission computed tomography 
(SPECT), 68Ga-DOTA-SSA PET/CT, or Fluorine-18-
L-Dihydroxyphenylalanine (18F-DOPA) PET/CT as 
the functional imaging modality according to the 
genotype, location, availability of 
radiopharmaceuticals, and clinical situation (B).
In patients with a high-risk for metastatic disease, such as large 
size of the primary tumor, extra-adrenal, multifocal (except 
skull base and neck PPGLs), and recurrent disease, the use of 
functional imaging modalities are suggested for detecting me-
tastases. 18F-fluorodeoxyglucose (FDG) PET has been used for 
this purpose; however, other functional imaging is currently 
recommended as the first choice of image because of its higher 
sensitivity and specificity [58]. The reported diagnostic perfor-
mance of each functional modality is different according to dis-
ease location, disease extent, and genotype (Table 4). 
123I/131I-MIBG scintigraphy has a comparable sensitivity for 
pheochromocytoma to fluorine-18-L-dihydroxyphenylalanine 
(18F-DOPA) PET/CT and 68Ga-DOTA-SSA PET/CT [59-62]. 
The diagnostic performance is enhanced with use of 123I-MIBG 
and single-photon emission computed tomography (SPECT) 
[62,63]. However, the sensitivity of 123I-MIBG scintigraphy in 
PGLs and metastatic PPGLs is relatively suboptimal, particular-
ly for SDHx-related PPGLs [64-67].
68Ga-DOTA-SSA PET/CT is the most sensitive tool for de-
tecting PPGLs in patients with unknown genetic status based on 
a recent systemic review and meta-analysis [68]. The elevated 
clinical value of 68Ga-DOTA-SSA PET/CT is also observed in 
extra-adrenal PGLs and head and neck PGLs [69-71]. Further-
more, 68Ga-DOTA-SSA PET/CT is preferred in the metastatic 
PPGLs [72]. In PPGLs with underlying SDHx mutations, 68Ga-
DOTA-SSA PET/CT can be recommended [73]. In contrast to 
SDHx-related PPGLs, 18F-DOPA PET/CT showed high tumor 
uptake in von Hippel-Lindau (VHL), rearranged during trans-
fection (RET), neurofibromatosis 1 (NF1), myc-associated pro-
tein X (MAX), hypoxia-inducible factor (HIF) 2A, prolyl hy-
droxylase (PHD)1/2, and fumarate hydratase (FH) mutated PP-
Table 4. Diagnostic Performance of Functional Imaging Modalities for Pheochromocytoma and Paraganglioma 
68Ga-DOTA-SSA 18F-DOPA 18F-FDG 123I/131I-MIBG
Detection rate, % 93.0–100 61.4–97.4 49.2–85.8 6.9–100
68Ga-DOTA-SSA, gallium 68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin receptor analogs; 18F-DOPA, fluorine-18-L-fluoro-
dihydroxyphenylalanine; 18F-FDG, 18F-fluorodeoxyglucose; 123I-MIBG, 123I-metaiodobenzylguanidine.
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GLs [74,75]. The exact mechanism for this phenotype is cur-
rently largely unrevealed, and many of these reports are based 
on extremely rare cohorts. 
Despite the clinical relevance of each functional imaging mo-
dality according to disease characteristics and genotypes, the 
practical availability of radiopharmaceuticals and clinical situa-
tion should be considered. 68Ga is produced by a generator sys-
tem that is affordable only in large centers, whereas 123I/131I-
MIBG, 18F-FDG, and 18F-DOPA are commercially available in 
many countries including Korea. Additionally, all of the func-
tional imaging modalities are effective despite relative inferiori-
ty to another in a specific situation. Therefore, it is recommend-
ed to appropriately utilize the recommended first choice or al-
ternative functional imaging modalities that are available for 
each institution (Fig. 1). 
3.4.  In PPGL patients planning for 131I-MIBG treatment, 
123I-MIBG imaging is necessary for treatment decision 
and response monitoring. 68Ga-DOTA-SSA PET/CT is 
necessary in patients with metastatic PPGLs when PRRT 
is planned (B).
In patients with metastatic PPGLs, targeted radiopharmaceuti-
cals treatment may be considered. In 123I-MIBG scintigraphy-
positive metastatic PPGLs, high dose 131I-MIBG therapy can be 
beneficial [76]. In particular, high-specific-activity 131I-MIBG 
(Azedra, Progenics Pharms Inc., New York, NY, USA) has re-
ceived U.S. Food and Drug Administration approval for meta-
static or locally aggressive PPGLs, which showed radiographic 
response rate of 92% and biochemical response of 68% in the 
phase-II study [77]. Pre- and post-treatment 123I/131I-MIBG is es-
sential to select appropriate candidate and response monitoring. 
In patients who are planning peptide receptor radionuclide ther-
apy (PRRT), 68Ga-DOTA-SSA PET/CT should be performed. 
177Lu, 90Y, 225Ac-labeled DOTA-D-Phe1-Tyr3-octreotide (TOC) 
and DOTA-0-Tyr3-octreotate (TATE) is the currently available 
PRRT as compassionate or off-label use [78,79]. Currently, 
177Lu-DOTA-TATE is commercially available in many countries 
including Korea, although it has not been officially approved 
for PPGL in most countries due to lack of clinical trials. The 
overall disease control rate of PRRT is 84%, and the biochemi-
cal response rate is between 61% and 64% in a meta-analysis 
[79]. Thus, it is recommended to consider PRRT in patients with 
metastatic PPGL who are not eligible for conventional chemo-
therapy and 131I-MIBG, when effective uptake is observed on 
Diagnosis staging (multifocality, metastases)














Metastatic + sympathetic PPGL + SDHx (-) 68Ga-DOTA-SSA
Metastatic + sympathetic PPGL + SDHx (+)
VHL, RET, NF1, MAX, HIF2A, PHD1/2, FH
1231-MIBG or
18F-DOPA
Fig. 1. Proposed clinical algorithm for nuclear (molecular) imaging studies for pheochromocytoma/paraganglioma. PPGL, pheochromocy-
toma/paraganglioma; PHEO, pheochromocytoma; HNPGL, head and neck paraganglioma; SDH, succinate dehydrogenase; VHL, von Hip-
pel-Lindau; RET, rearranged during transfection; NF1, neurofibromatosis 1; MAX, myc-associated protein X; HIF2A, hypoxia-inducible 
factor 2A; PHD1/2, prolyl hydroxylase domain 1/2; FH, fumarate hydratase; 123I-MIBG, 123I-metaiodobenzylguanidine; 68Ga-DOTA-SSA, 
gallium 68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin receptor analogs; 18F-DOPA, fluorine-18-L-fluorodihy-
droxyphenylalanine; 18F-FDG, 18F-fluorodeoxyglucose; PRRT, peptide receptor radiotherapy.
Except for HIF2A and PHD1/2
:18F-FDG
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68Ga-DOTA-SSA PET/CT.
4.  Pathological grading system of pheochromocytoma/
paraganglioma
4.1.  The PASS and the GAPP cannot be used to confirm 
the diagnosis of malignancy (B).
To predict risks for PPGL metastases, two separate histological 
prediction systems have been established as followed; the PASS 
grading system and the GAPP (Table 5) [25,26]. First, the earli-
est grading system for detecting the potential of metastatic be-
havior of pheochromocytoma was the PASS grading system 
created by Thompson [26] in 2002. PASS originally designed 
for pheochromocytomas only incorporates 12 individually his-
tologic features endowed with different points (one or two 
points), which were based on the occurrence of parameters in a 
pre-defined metastatic cohort. With a total score of 20 of PASS, 
a pheochromocytoma is considered as biologically aggressive 
when applying a cut-off score of ≥4 whereas those with a score 
<4 are considered not to have metastatic potential [26,80]. The 
PASS grading system has been validated in previous studies, of 
which the results were inconsistent [81-83]. These studies gen-
erally indicate that the PASS system is of high sensitivity 
(100%) and low specificity with the potential to correctly “rule 
in” metastatic pheochromocytomas [58,84]. However, this sys-
tem also carries its shortcomings. First, it has inter- and intra-
observer variations [33]. Second, other important factors such 
as gene mutation, tumor characteristics, and clinical characteris-
tics of patients were ignored, whereas only histological charac-
teristics were included [58,84]. These advantages have been de-
bated in terms of the clinical value of the PASS grading system, 
which limited application to all PPGL cases for clinical prog-
nostication [80]. Then, the GAPP was developed by Kimura et 
al. [25] for both PPGLs, which included some histological fea-
tures from the PASS and added immunohistochemical (Ki-67 
index) and biochemical (catecholamine type) data. The GAPP 
model stratifies the PPGLs into three classes: well-differentiated 
Table 5. Comparison of Two Systems Predicting Pheochromocytoma and Paraganglioma Metastatic Potential 
Parameter PASS (score if present)Only PHEO 
GAPP (points scored)
Both PHEO and PGL 
Criteria (no. of subject) 1. Large nests or diffuse growth (2)
2. Central or confluent tumor necrosis (2)
3. High cellularity (2) 
4. Cellular monotony (2)
5. Tumor cell spindling (2) 
6. Mitotic figures >3/10 HPF (2)
7. Atypical mitotic figure(s) (2)
8. Extension into adipose tissue (2)
9. Vascular invasion (1)
10. Capsular invasion (1)
11. Profound nuclear pleomorphism (1)
12. Nuclear hyperchromasia (1)
1. Histological pattern
- Zellballen (0)
- Large and irregular cell nest (1)
- Pseudorosette (even focal) (1)
2. Cellularity
- Low (<150 cells/U) (0) 
- Moderate (150–250 cells/U) (1)
- High (more than 250 cells/U) (2)
3. Comedo necrosis
- Abscence (0)/Presence (2)
4. Vascular or capsular invasion
- Abscence (0)/Presence (1)
5. Ki67 labelling index (%)
- <1 (0)/1–3 (1)/>3 (2)
6. Catecholamine type
- Epinephrine type (0)
- Norepinephrine type (1)
- Non-functioning type (0)
Total score 0–20 0–10
Risk groups 0–3: benign fashion
4–20: biologically aggressive behavior
0–2: Well-differentiated type
3–6: Moderately differentiated type
7–10: Poorly differentiated type
Sensitivitya 100% 90%
Specificitya 75% 87%
PASS, Pheochromocytoma of the Adrenal Gland Scaled Score; PHEO, pheochromocytoma; GAPP, Grading of Adrenal Pheochromocytoma and Para-
ganglioma; PGL, paraganglioma; HPF, high-power field.  
aFor detection of malignancy.
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(0–2 points), moderately differentiated (3–6 points), and poorly 
differentiated (7–10 points) [25]. Like the PASS system, the 
GAPP model also has a high sensitivity (90%) and low specific-
ity [58]. Wachtel et al. [85] recently published a retrospective 
cohort study, including 143 subjects with PPGLs about the 
comparison PASS and GAPP scoring system. They found that a 
higher GAPP score was associated with metastatic PPGLs, 
whereas the PASS score was not. According to their study, 
PASS had low-moderate reliability between observers, while 
the GAPP score had significantly less inter-observer variability 
than PASS. For these reasons, they recommended that a shift 
from PASS to GAPP scores to predict more accurate prognosti-
cation for PPGL patients, but both of them were still insufficient 
because neither of them was associated with mortality from 
PPGL. None of them is 100% predictive for risk stratification, 
but both of them display excellent sensitivity [84].
4.2.  The loss of SDHB protein by IHC staining in tumor 
cells is suggested to detect the presence of germline 
mutations in one of the SDHx genes. PPGLs associated 
with SDHB mutation have a high risk of metastases (B).
Pathogenic germline variants in any of the SDHx subunit genes 
(SDHA/B/C/D) have been implicated in hereditary tumorigene-
sis of PPGLs [86]. The majority of patients with hereditary 
PPGL syndromes (30% to 40%) have germline mutations in 
these SDHx subunit genes [86]. Germline mutations of SDHB 
have been widely accepted as a high-risk factor for metastases, 
leading to metastatic PPGLs in 40% or more of affected patients 
[57,87,88]. Furthermore, SDHB germline mutation is a poor 
prognostic factor in patients with metastatic PPGLs [11]. In 
terms of the 5-year probability of survival after the diagnosis of 
the first metastases were 0.36 (0.15 to 0.57) in SDHB mutation 
carriers and 0.67 (0.47 to 0.81) in the absence of SDHB muta-
tion (relative risk, 2.6; P=0.019) [24]. SDHB mutation carriers 
also have a shorter median survival of 42 months, compared to 
244 months for SDHB mutation non-carriers. This shorter me-
dian survival was significantly associated with the presence of 
SDHB mutations independent of age at diagnosis.
Germline mutations in any of these SDHx genes lead to desta-
bilization of the SDH protein complex and loss of SDHB ex-
pression at IHC. Therefore, loss of SDHB IHC staining in tu-
moral tissue suggests the presence of germline mutations in one 
of the SDHx genes with 100% sensitivity and 84% specificity 
[80,89,90]. Several studies have reported that a combination of 
biochemical, histological, and SDHB IHC might be useful for 
predicting metastatic PPGLs [24,25]. One of them was the modi-
fied GAPP (M-GAPP) proposed by Koh et al. [24] in 2017. Fur-
thermore, SDHB IHC test is technically easy and cost-effective 
because of its simplicity of the standard procedure and data in-
terpretation. Hence, it can be routinely performed in all PPGLs, 
even in the absence of familial or clinical indications for a spe-
cific form of inherited PPGL. Therefore, it is necessary to identi-
fy SDHx (SDHB, SDHC, and SDHD) germline mutation by the 
loss of SDHB IHC staining in all patients with PPGLs [91]. 
5. Genetic testing for pheochromocytoma/paraganglioma
5.1.  Genetic testing is recommended in all patients 
diagnosed with PPGLs (A).
PPGLs have striking characteristics regarding the importance of 
genetic testing, which are their high heritability and genetic het-
erogeneity [92]. PPGLs are the most frequently heritable tumors 
in humans, with at least 30% to 40% of inherited forms of the 
disease [93]. For this reason, it is recommended that all patients 
are ‘engaged in shared decision making’ and ‘considered’ for 
genetic testing, respectively [57,94]. There are several reasons 
genetic testing should be considered in all patients with PPGLs. 
First of all, more than one third of all patients with PPGLs have 
a disease-causing germline mutation in PPGL susceptibility 
genes because of their strong genetic determinism [95]. Second, 
about 40% or more of patients with SDHB mutation have meta-
static phenotype as the principal predictor of malignancy in 
PPGL patients [57,93,94]. Third, patients with genetic or syn-
dromic PPGL have higher risks in development for PPGL com-
plications compared to those with apparently sporadic disease 
[94,96]. Fourth, about 11% to 13% of patients with apparently 
sporadic PPGLs such as single benign PPGL without a family 
history have a mutation in susceptibility genes according to a 
meta-analysis [97]. Lastly, the identification of the genetic mu-
tation in the proband may have implications for their family 
members related to the necessity of surveillance [98].
5.2.  Genetic testing should be also considered for first-
degree relatives of patients with hereditary PPGLs (B). 
As mentioned in the previous section 5.1, PPGLs are the most 
heritable tumors with syndromic clinical features such as NF1, 
VHL, multiple endocrine neoplasia type 2 (MEN2), or paragan-
glioma syndrome (PGL). These pheochromocytoma-associated 
syndromes usually have a higher frequency of family history 
through the mostly autosomal dominant transmission [99]. For 
this reason, the Endocrine Society also recommends directly 
targeted germline mutation testing beyond sequential genetic 
testing in patients with PPGLs who have a positive family his-
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tory or syndromic presentation [57]. Muth et al. [98] suggest 
that genetic testing should be applied to first-degree relatives in 
all hereditary PPGL and to second-degree relatives in case of 
SDHD, succinate dehydrogenase complex assembly factor 2 
(SDHAF2)-related PPGLs as well as SDHB, SDHA, SDHC, FH, 
transmembrane protein 127 (TMEM127), and MAX mutation 
related to metastatic disease.
5.3.  Validated targeted NGS is a preferred method for the 
genetic diagnosis of PPGLs (B). 
Since 1990, germline mutation in a dozen PPGL susceptibility 
genes have been reported [57,95]. Moreover, as techniques for 
genetic testing have been advanced, higher mutation discovery 
rates and a better understanding of the clinical phenotypes of 
PPGLs have been achieved [93]. After the Endocrine Society 
proposed a clinical feature-driven diagnostic algorithm for pri-
orities for specific genetic testing for PPGL, the advent of NGS 
methods offers a single assay for the screening of all PPGL sus-
ceptibility genes [100]. Therefore, decision algorithms for 
PPGL genetic testing has been changed from ‘from the patient 
to the candidate genes’ into ‘from the mutated genes to the af-
fected patient [95]. Likewise, the implementation of NGS has 
been a paradigm shift in genetics research of PPGLs [92]. Ac-
cordingly, the NGS in PPGL (NGSnPPGL) study group recom-
mended genetic testing should be performed in all patients with 
PPGLs independent of clear family history [92]. They preferred 
targeted NGS as a method for genetic diagnosis of PPGLs with 
blood (fresh collected within 7 days or frozen) or a frozen leu-
kocyte pellet. The suggested targeted panels should include 
coding exons and intron boundaries of the targeted genes. As in 
conventional genetic testing, whenever possible, confirmation 
of the NGS-identified variant in a separate aliquot of the pa-
tient’s DNA is highly recommended by using an orthogonal 
method such as Sanger sequencing [92].
5.4.  We recommend targeted NGS panels of gene sets 
based on the current level of evidence of their 
pathogenic driver status: 10 basic panel (FH, MAX, 
NF1, RET, SDHA, SDHB, SDHC, SDHD, TMEM127, 
VHL) and five extended panel (egl-9 family hypoxia 
inducible factor 1/prolyl hydroxylase domain 2 
[EGLN1/PHD2], endothelial PAS domain-containing 
protein 1 [EPAS1], kinesin family member 1B [KIF1B], 
MET, SDHAF2) (C).
The NGSnPPGL study group proposed three sets of gene panels 
for the diagnosis of PPGLs; basic (evidence level 3 and 4 for 
germline mutations; including 10 genes such as FH, MAX, NF1, 
RET, SDHA, SDHB, SDHC, SDHD, TMEM127, and VHL), ex-
tended (evidence level 2 for germline mutations; including five 
more genes such as EGLN1/PHD2, EPAS HIF2A, KIF1B, MET, 
and SDHAF2), and comprehensive panels (all somatic muta-
tions and all levels of evidence; extended genes added to 12 
more genes including alpha thalassemia/mental retardation syn-
drome X-linked [ATRX], v-raf murine sarcoma viral oncogene 
homolog B1 [BRAF], cyclin dependent kinase inhibitor 2A 
[CDKN2A], EGLN2/PHD1, fibroblast growth factor receptor 1 
[FGFR1], H3 histone, family 3A [H3F3A], Harvey rat sarcoma 
viral oncogene homolog [HRAS], isocitrate dehydrogenase 2 
[IDH2], lysine [K]-specific methyltransferase 2D [KMT2D], 
malate dehydrogenase 2 [MDH2], MER proto-oncogene, tyro-
sine kinase [MERTK], and tumor protein p53 [TP53]) [92]. 
Herein, they modified ClinVar review status to adapt for their 
consensus statement on PPGLs driver genes. They used five 
levels (evidence level 0–5) based on numbers of applicable 
sources; level 0 with not applicable; level 1 with single source; 
level 2 as two or more sources without funcitonal validation; 
level 3 with two or more sources with some functional valida-
tion; and level 4 with established evidence from clinical, genet-
ic, computational prediction as well as functional evidence and/
or analysis of population frequency. A study about the diagnos-
tic methods of PPGLs demonstrated that NGS assay signifi-
cantly improved the performances of PPGL genetic testing 
compared with conventional methods with a higher rate of the 
identified mutation [101]. From that study, Ben Aim et al. [101] 
designed and suggested their custom multigene panel, ‘MAS-
TER Plus SDHv2,’ including 17 PPGL genes; VHL, NF1, RET, 
SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127, FH, MAX, 
EPAS1, EGLN1, EGLN2, MDH2, ATRX, and HRAS genes. Un-
fortunately, there are limited data on genetic studies of PPGLs 
in Korea [102]. Recently, a study with the largest number of 
Korean PPGL patients (n=161) reported that approximately 
21% of sporadic PPGLs without any family history still har-
bored germline mutation of the PPGL-related genes [103]. This 
could be a convincing evidence for performing targeted NGS 
study in Korean patients with PPGLs like other ethnic groups. 
Another recent published data also reported genetic analysis and 
clinical characteristics of PPGLs in Korea [104]. In this study, 
among 57 patients with PPGLs, 28 different germline mutations 
were identified in 11 susceptibility genes (EPAS1, KIF1B, MAX, 
NF1, RET, SDHA, SDHB, SDHC, SDHD, TMEM127, and 
VHL). The prevalence of germline mutation was 32.6%, and the 
most frequently mutated genes were SDHB (n=11, 31.4%) fol-
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lowed by RET (n=8, 22.3%), VHL (n=6, 17.1%), NF1 (n=2, 
5.7%), and EPAS1 (n=2, 5.7%) [104]. 
Taking all these considerations into account, we recommend 
two sets of gene panels (basic and extended) based on the cur-
rent level of evidence of their pathogenic driver status, which 
adopted from the consensus statement of NGS based diagnostic 
testing of hereditary PPGLs by the NGSnPPGL study group 
(Table 6) [92]. When the primary mutation is not found in tar-
geted NGS, comprehensive genetic studies such as whole-
exome sequencing or whole-genome sequencing can be further 
considered to improve the understanding of the pathogenicity in 
any possible variants whenever possible [92]. A recent study 
performing WES in 36 patients with PPGL who had negative 
tests from previous Sanger sequencing or targeted gene panel 
revealed that two more likely pathogenic variants were addi-
tionally detected [105].
CONCLUSIONS
As a result of overarching research, PPGLs has been known as 
the representative hereditary tumor and newly classified as a 
malignant tumor. Also, great progress has been made regarding 
biochemical tests, functional imaging, and genetic testing. Ac-
cordingly, we can diagnose PPGLs more appropriately, detect 
multifocal or metastatic lesions, and predict prognosis better. 
We hope that this position statement provides the current knowl-
edge and be helpful in clinical practice.
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